Jazz Pharmaceuticals plc
NASDAQ:JAZZBiotechnology
+$0.05 today
- Market cap
- $15.90B
- Beta
- 0.33
- P/E (TTM)
- 476.3
- EPS (TTM)
- $0.48
Volume 0.72M
Average 0.92M
JAZZ Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Jazz Pharmaceuticals plcNASDAQ: JAZZ
Total Equity · Q3 FY2026 · quarter ended Sep 2026
Total equity rises 5.9% from a year ago
Total equity stood at $4.19B at the end of Q3 FY2026, up 5.9% from a year earlier and down 12.7% from the prior quarter. Over 3 fiscal years it compounded at +11.9% a year.
Context
- Total equity amounted to 34.9% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
- Total equity increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +5.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 4.32B USD
- Year-over-year change
- +5.5%
- 4-year CAGR
- +2.2%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.32B | +5.5% |
| FY2024 | 2024-12-31 | 4.09B | +9.5% |
| FY2023 | 2023-12-31 | 3.74B | +21.1% |
| FY2022 | 2022-12-31 | 3.09B | -22.2% |
| FY2021 | 2021-12-31 | 3.97B | — |
Total Equity vs competitors
How JAZZ compares with its peers on the latest reported figures
- JAZZ's Sep 2026 total equity of $4.19B is the 3rd highest of the 9 companies compared; the peer median is $1.14B.
- Its year-over-year change of +5.9% is the 7th highest of 9, against a peer median of +21.3%.
- Total equity amounts to 34.9% of total assets for JAZZ, versus a peer median of 58.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $6.34B | +52.1% | +5.7% | 80.6% | |
| Jun 2026 | $5.96B | +12.4% | -40.2% | 47.6% | |
| Sep 2026 | $4.19B | +5.9% | +11.9% | 34.9% | |
| Sep 2026 | $3.88B | +29.1% | +24.0% | 68.9% | |
| Sep 2026 | $1.27B | +25.9% | +10.4% | 75.7% | |
| Jun 2026 | $999.24M | +29.3% | +29.3% | 72.8% | |
| Jun 2026 | $967.52M | +16.8% | +19.4% | 44.3% | |
| Sep 2026 | $572.13M | -5.8% | +122.8% | 35.9% | |
| Mar 2026 | $21.2M | -73.2% | -26.8% | 9.7% | |
| Peer median (excluding JAZZ) | $1.14B | +21.3% | +14.9% | 58.3% | |
Competitors are the stored peer set for JAZZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 591.45M | 881.48M | 1.51B | 2.41B | 1.39B |
| Short-term Investments | 0 | 0 | 120M | 580M | 1.05B |
| Net Receivables | 563.36M | 651.49M | 705.79M | 716.77M | 830.75M |
| Inventory | 1.07B | 714.06M | 597.04M | 480.45M | 416.96M |
| Other Current Assets | 252.39M | 267.19M | 320.81M | 261.54M | 323.95M |
| Total Current Assets | 2.61B | 2.61B | 3.44B | 4.63B | 4.17B |
| Property, Plant & Equipment (Net) | 343.42M | 301.38M | 234.99M | 227M | 258.74M |
| Goodwill | 1.83B | 1.69B | 1.75B | 1.72B | 1.83B |
| Intangible Assets | 7.15B | 5.79B | 5.42B | 4.76B | 4.43B |
| Long-term Investments | 5M | 5.5M | 0 | 4.33M | 4.3M |
| Tax Assets | 0 | 0 | 477.83M | 560.25M | 869.13M |
| Other Non-current Assets | 358.95M | 435.14M | 73.94M | 119.64M | 102.28M |
| Total Non-current Assets | 9.69B | 8.23B | 7.96B | 7.38B | 7.49B |
| Total Assets | 12.3B | 10.84B | 11.39B | 12.01B | 11.66B |
| Account Payables | 100.3M | 90.76M | 102.75M | 77.87M | 122.06M |
| Short-term Debt | 31M | 31M | 604.95M | 31M | 1.03B |
| Tax Payables | 9.61M | 7.72M | 35.07M | 18.76M | 56.39M |
| Deferred Revenue | 2.09M | 463K | 0 | 0 | 0 |
| Other Current Liabilities | 193.1M | 169.41M | 142.33M | 189.76M | 245.99M |
| Total Current Liabilities | 809.3M | 933.19M | 1.54B | 1.04B | 2.24B |
| Long-term Debt | 6.02B | 5.69B | 5.11B | 6.08B | 4.33B |
| Deferred Tax Liabilities | 1.3B | 944.34M | 847.71M | 676.74M | 594.47M |
| Deferred Revenue (Non-current) | 463K | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 117M | 106.81M | 104.75M | 86.61M | 124.52M |
| Total Non-current Liabilities | 7.52B | 6.82B | 6.12B | 6.88B | 5.1B |
| Total Liabilities | 8.33B | 7.75B | 7.66B | 7.92B | 7.34B |
| Common Stock | 61K | 61K | 61K | 61K | 6K |
| Retained Earnings | 830.23M | 733.59M | 878.66M | 1.13B | 646.18M |
| Accumulated OCI | (400.36M) | (1.13B) | (842.15M) | (947.67M) | (568.6M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 3.97B | 3.09B | 3.74B | 4.09B | 4.32B |
| Total Debt | 6.15B | 5.81B | 5.79B | 6.16B | 5.42B |
| Net Debt | 5.56B | 4.93B | 4.29B | 3.75B | 4.03B |
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
Intrinsic Alpha fair value
Locked
Current Price
$247.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.